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INTRODUCTION 
Diabetic ketoacidosis (DKA) is most common among 
patients with type 1 diabetes mellitus (DM) and de-
velops when insulin levels are insuffi  cient to meet the 
body’s basic metabolic requirements. It is characte-
rized by modest or rarely extreme hyperglycemia, 
hyperketonemia, ketonuria and metabolic acidosis 
(1). Excessive glucose secretion by kidneys overco-
mes the glucose tubular maximum reabsorption cre-
ating a hyperosmolar state in renal tubules, which
causes osmotic diuresis with signifi cant fl uid and ele-
ctrolyte loss. Almost absolute lack of insulin forces 
the body to metabolize triglycerides and amino acids 
instead of glucose for energy, which in return results 
in excessive production of ketones (2). Hyperglycemic 
nonketotic state is more oft en seen in type 2 DM whe-
re even minimal pancreatic insulin secretion does not 
allow excessive ketone production (3).
CASE REPORT
A 19-year-old male with a fi ve-year history of poor 
regulation of DM was admitted to our Intensive Care 
Unit (ICU) for clinical and laboratory signs of severe 
DKA, extreme hyperglycemia, hypovolemia, dehydra-
tion, hypotension and lactic acidosis. He was found at 
home unresponsive, tachypneic, with nausea and vo-
miting, which had lasted for four days until hospital 
arrival. During that time, there was no liquid or food 
intake or insulin application. Laboratory tests were 
as follows: RBC 4.9x1012/L, Hb 154 g/L, Htc 0.53 L/L, 
MCV 110.6 fL, L 25.6x109/L, platelet count 348x109/L, 
C-reactive protein (CRP) 132.2 mg/L; venous blood 
gas analysis: pH 6.83, pCO2 2.3 kPa, BE -30.5 mmo-
l/L, pO2 11.24 kPa, bicarbonates 2.9 mmol/L, total CO2 
3.4 mmol/L, O2 saturation 84.7 percent, blood glucose 
87.9 mmol/L, creatinine 317 μmol/L, urea 11.8 mmo-
l/L, lactic acid 3.2 mEq/L, AST 48 U/L, ALT 62 U/L, 
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K 7.2 mmol/L, Na 116 mmol/L, Cl 75 mmol/L, and 
procalcitonin (PCT) 34.9 ng/mL. Upon arrival to the 
ICU, the patient was comatose and smelled of acetone, 
with Kussmaul breathing 27 breaths/min, tachycardia 
105/min, hypotension 85/45 mm Hg, oxygen satura-
tion of 86% on pulse oximetry at room air (hypoten-
sion!). Glasgow Coma Score was 7 and central venous 
pressure (CVP) was -4 cm H20. Urgent chest x-ray was 
normal. Neurological exami nation showed slightly 
delayed refl exes and decreased muscle tone consistent 
with altered mental status. Electrocardiography was 
within the normal range. Urine bacteriology, blood 
and stool cultures were sterile. In order to establish 
normotension and diuresis to induce glycosuria and 
ketonuria and to correct lactic acidosis, the patient re-
ceived 1500 mL of normosaline volume replacement 
in the fi rst 90 minutes. Normosaline infusions conti-
nued up to the total of 7 L in the fi rst 24 hours at the 
average infusion rate of 245 mL/hour and periodical 
control of CVP. At the very beginning, the patient re-
ceived an intravenous bolus of 12 i.u. of rapid acting 
insulin, which was continued as a rapid acting insulin 
infusion at the average dose of 12 i.u. per hour, and 
close monitoring of blood glucose level every 2 hours. 
Total amount of rapid acting insulin applied intrave-
nously in the fi rst 24 hours was 300 i.u. Due to the se-
verely low pH and consecutive high serum potassium, 
sodium bicarbonate infusion was included in therapy 
at the rate of 30 mL/hour. In the next fi ve hours, the 
level of 7.2 and 5.9 mmol/L was reached for pH and 
potassium, respectively, which allowed bicarbonate 
therapy to be stopped. However, as blood glucose level 
and ketoacidosis improved, severe serum depletion of 
potassium occurred, which required replacement of 
400 mL of KCL in the fi rst 48 hours and monitoring 
of serum potassium level every 6 hours. Following 
improvement of laboratory parameters, the patient’s 
mental status recovered, and so did his food and water 
intake per os. Insulin therapy was switched to subcuta-
neous application. Aft er two days of treatment, com-
plete resolution of DKA was reached, the patient was 
transferred to the Department of Endocrinology and 
soon discharged from the hospital. 
DISCUSSION
Regular clinic attendance is recommended to facilitate 
self‐management of diabetes. Poor attendance is com-
mon among young adults with type 1 DM, which pre-
cipitates acute diabetic complications (4). Psychosocial 
factors such as socioeconomic status, parental separa-
tion and lack of family cohesiveness, unemployment, 
psychological and mental health factors including eat-
ing disorders and substance abuse play a crucial role in 
the management of DM in young adults.
Th e high frequency of DKA in known type 1 DM in-
dicates the need of particular focus on adolescents (5). 
Spaic et al. found that structured transition program 
for young adults with type 1 diabetes improved clinic 
attendance, glycemic control, diabetes-related distress, 
quality of life, and satisfaction with care in regard to 
standard care (6).
In our patient, history data were not indicative of so-
cioeconomic or family problems, but his compliance 
was very poor and probably associated with psycho-
logical profi le.
Hypovolemia induced by osmotic diuresis includes 
the loss of fl uid, sodium and potassium (7). However, 
serum potassium is usually raised because of ketoaci-
dosis, which is responsible for cell potassium reaching 
serum. Low serum potassium level at arrival means 
severe exhaustion of potassium cell backup. Hypo-
volemia and consecutive hypotension stimulate the 
release of counter-regulatory diabetogenic hormones 
such as adrenaline and cortisol, thus causing further 
increase in serum glucose level. Th erefore, immediate 
volume replacement is of crucial importance and as 
urgent as the administration of rapid acting insulin 
(8). Any therapy during hypotension must be applied 
intravenously. Normosaline infusion is generally the 
best choice because of the usually low sodium level 
and high blood glucose level (9). 
Th e optimal rate of isotonic saline infusion depends 
on the patient’s clinical condition. Primary goal is to 
reach normotension and diuresis as soon as possible. 
Although the fl uid challenge therapy might be a do-
uble-edge sword, we found it safe and useful for our 
young patient in severe hypovolemic state. When re-
placing the volume, special attention must be paid to 
older patients or patients with heart or renal insuffi  -
ciency (10). 
Insulin therapy should be initiated with IV bolus of re-
gular insulin (0.1 units/kg body weight), followed by 
continuous infusion of regular insulin of 0.1  units/
kg per hour (11). Th e bolus dose can be omitted if a 
higher dose of continuous IV regular insulin is ini-
tiated (0.14  units/kg  per hour). Higher doses do not 
produce a more prominent hypoglycemic eff ect due to 
saturation of insulin receptors. In mild DKA, patients 
can be safely treated with subcutaneous, rapid-acting 
insulin analogs. Th ere is no diff erence in treating DKA 
with IV regular insulin and rapid-acting insulin ana-
logs, along with much lower cost of regular insulin 
therapy. 
When serum glucose in DKA falls to less than 12 
mmol/L, but bicarbonate and pH values are not nor-
malized, glucose infusion is recommended (12). Each 
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500 mL of 5% and 10% glucose infusion must contain 
8 and 16 IU of rapid acting insulin, respectively, in or-
der to provide glucose utilization and therefore eno-
ugh energy to stop ketogenesis.
In patients with euglycemic DKA, both insulin and 
glucose therapy is necessary, and the response to 
low-dose insulin therapy improves with adequate 
rehydration (13). 
We strongly advise to synchronize potassium repla-
cement with laboratory monitoring. When potassi-
um level is high, any replacement in advance is not 
recommended.
Insulin therapy promotes potassium uptake by the 
cells along with glucose and may trigger cardiac arrhy-
thmias. In severe hypokalemia (below 3.3 mEq/L), 
potassium administration in 500 mL of normosali-
ne infusion at the rate of 10 to 20 mEq/hour will be 
suffi  cient for most patients. It must be followed by se-
rum potassium measurements every two hours and 
stopped immediately when normal range is reached 
(14). Patients at risk of volume overload can receive 
more concentrated potassium infusion via central ve-
nous catheter at the same dose but at a lower rate per 
hour. Th e indications for bicarbonate therapy in DKA 
are controversial and there is not enough evidence for 
its benefi t (15). If arterial pH is 6.9 or less, as in our 
patient, it might be of certain help, although most au-
thors will cease this therapy as soon as the pH value 
reaches 7.0. In patients with potentially life-threa-
tening potassium level over 6.4 mEq/L, bicarbonate 
therapy should be used until the level falls below 6.4 
mEq/L (16).
Initially, monitoring involves measurements of serum 
glucose every hour until the profi le becomes relative-
ly stable. Serum electrolytes, creatinine, and venous 
blood gas analysis should be measured every two to 
four hours, depending on DKA severity and clinical 
response (17). 
When ketoacidosis is resolved and the patient is ready 
for oral intake, subcutaneous insulin schedule should 
be started and IV insulin infusion should be continued 
for one or two hours aft er initiating subcutaneous in-
sulin to prevent recurrence of hyperglycemia or keto-
acidosis. In patients previously treated with insulin, 
the established insulin regimen may be restarted. 
It is well-established that DKA is associated with leu-
kocytosis and an increase in acute phase proteins, inc-
luding CRP, tumor necrosis factor alpha, interleukin 
1 beta (IL-1β), IL-2, IL-6 and IL-8.2 (18). Moderate 
increase of serum levels of procalcitonin in DKA is 
less known but practitioners should be aware that in-
creases in CRP and PCT may occur in patients with 
DKA in the absence of bacterial infection, thus avoid-
ing unnecessary examinations such as blood cultures 
and treatments (antibiotics) if other signs of infection 
are not present (19).
Extremely high value of procalcitonin as in our pa-
tient, in the proved absence of bacterial infection is 
very rare. However, it may be a consequence of syner-
gistic eff ect of ketoacidosis and extremely high blood 
glucose level. It has been reported that correction of 
plasma glucose levels leads to a decrease of PCT con-
centrations in patients presenting with acute hyper-
glycemia (20), which is exactly what happened in our 
patient. 
CONCLUSION
Th erapeutic approach to DKA should be individual, 
the patient must receive adequate volume, adequate 
dose of insulin, appropriate electrolyte replacement, 
and must be carefully monitored. At the same time, 
precipitating events or triggers of ketoacidosis such 
as infection should be intensively looked for. DKA is 
frequently accompanied by moderate increase of se-
rum levels of CRP and procalcitonin, which does not 
necessarily refl ect the presence of bacterial infection. 
As a result of actual therapy guidelines, further possi-
ble complications of DKA have become less common. 
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Prikazan je slučaj 19-godišnjeg bolesnika od dijabetesa koji nije redovito primjenjivao inzulin. Bolesnik je doveden na naš 
Objedinjeni hitni prijam u komatoznom stanju, s ekstremnom hiperglikemijom, teškom dijabetičkom ketoacidozom, lak-
tacidozom i dehidracijom. Liječen je intenzivnom nadoknadom volumena i korekcijom svih metaboličkih poremećaja do 
potpunog oporavka. U velikoj većini slučajeva teških dijabetičkih ketoacidoza može se očekivati relativno brza i uspješna 
korekcija ako se primijeni intenzivno liječenje i ako ketoacidoza nije potaknuta ozbiljnom bolesti. U članku su navedene 
neke bitne suvremene smjernice u liječenju i naglašena je važnost individualnog pristupa. Raspravljena je i uloga visoke 
serumske vrijednosti prokalcitonina u dijabetičkoj ketoacidozi.
Ključne riječi: dijabetička ketoacidoza, hiperosmolarno stanje, hipovolemija, liječenje dijabetičke ketoacidoze
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